AR and prostate carcinoma: For example, interleukin (IL)-6 was found to induce the drug resistance of prostate cancer by activating the androgen receptor (AR), and IL-4 was found to be associated with the development of CRPC by regulating coactivators of AR such as The nuclear factor-kappaB (NF-κB) [10,11].